Discussing the burden of hypertrophic cardiomyopathy (HCM), expert in this field Pablo Garcia-Pavia, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, sheds light on the diagnosis and treatment of HCM. Further discussion centres around myosin inhibitor drugs, specifically their mechanism of action, associated advantages and limitations, and their relevance to HCM subtypes are outlined. Relevant studies presented at the European Society of Cardiology (ESC) Congress 2023, as well as ongoing clinical trials and research initiatives focused on myosin inhibitors and HCM treatment, are also summarised.

It'll also highlight the latest ESC Guidelines and how they play a crucial role in shaping clinical practice, before looking ahead to the most promising advancements in the field of HCM treatment.

This medical education podcast was sponsored by Myokardia and Bristol Myers Squibb.